摘要
目的 :探讨多肿瘤抑制基因编码的 P16蛋白表达与卵巢癌生物学特性及患者预后的相关性。方法 :应用免疫组织化学S- P法检测 5 8例人卵巢癌组织中 P16蛋白的表达。 结果 :(1) P16蛋白在不同病理组织学类型的卵巢癌组织中阳性表达率不同 ,表现为低分化腺癌的阳性表达率低于交界性肿瘤 ,两者相差显著 (P<0 .0 5 )。 (2 )术中发现有淋巴结及网膜转移的患者 ,其卵巢癌组织中 P16蛋白的阳性表达率低于无转移者 ,两者相差非常显著 (P<0 .0 1) ;但其阳性率在原发灶与转移灶间相差不显著 (P>0 .0 5 )。 (3)术后存活期小于或等于 2年的患者 ,其卵巢癌组织中 P16蛋白的阳性表达率低于术后存活时间大于 2年者 ,两者相差显著 (P<0 .0 5 )。结论 :P16蛋白在抑制卵巢癌的发生发展中起重要作用 ,检测卵巢组织 P16蛋白的表达 。
Objective: To detect the expression of protein P16 in 58 cases of ovarian cancer, study its clinic significance and the function of protein P16 in ovary carcinogenesis. Methods: The expression of protein P16 in human ovarian cancer tissue was observed with immunohistochemical method and streptavidin peroxdase conjugataed method. Results: The expression of protein P16 was related to histologic types of ovarian cancer( P <0.05), the differences in positive rate were found mainly between adenocarcinoma and border line tumor; the former was lower. It was related closely to lymph nodal and great omental metastases( P <0.01), the positive rate of primary sites in patiants with metastases was lower than those who had no metastases; but there was no difference in positive rate between primary sites and metastases( P >0.05). The expression was also related to the survival time after operation( P <0.05). Conclusion: Protein P16 may play an important role in human ovary carcinogenesis. The expression of protein P16 in ovarian tumor tissue may serve as one of assessable factors for prognosis in patients with ovarian carcinoma. [
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2000年第12期1158-1160,共3页
Academic Journal of Second Military Medical University
